Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Market Reports
How to proactively address EU HTAR implementation challenges before 2025
Data landscape challenges within the European Union (EU) have historically been driven by the different laws, processes and regulatory standards of its 27 member states (MS). As a result, drug therapeutics and health technology developers have faced the challenge of duplication of assessment efforts
Adding more to the cell and gene therapy playbook
With notable advances in various forms of administration, including making the use of viral vectors safer, non-viral delivery with lipid nanoparticles and the growing application of electroporation, Dr Kevin Robinson (KSR) recently caught up with Jason Potter (JP), Director of Cell Biology R&D at Thermo Fisher Scientific, to learn more about how the company is helping the pharmaceutical industry to develop cell and gene therapies
What to consider for successful GMP Annex 1 implementation
In advance of her presentation at Manufacturing Chemist Live, Dr Nicole Hunter (NH), Head of Global Regulatory and Validation Services at Watson-Marlow Fluid Technology Solutions, and colleague Claire Hutchison (CH), Life Science Specialist, provide their insights on the updates to the European Commission’s Good Manufacturing Practices (GMP) Annex 1 and the role of single-use systems
Highly potent formulation development in oncology
Formulation development is a dynamic and experimental process. However, certain challenges are presented to CDMOs that add a layer of unnecessary pressure to the development process — some of which are avoidable. Louise Carpenter from PCI Pharma Services discusses
Going beyond the guidance: getting business benefit from change management
Change management offers a broad, system-wide perspective that includes the oversight and management of all changes and the change process. Michelle Anastasi of PharmaLex explores what good change management looks like and who should be involved
QMM: a natural development of pharmaceutical regulation?
During the pandemic, we saw a rapid evolution of inspection approaches that showed how the sector — and indeed the regulators — can adapt to new operational models
SCHOTT Pharma reveals strong financial performance in fiscal year 2022
In a record year of growth, sales increased by 27% to EUR 821 million and EBITDA by 33% to EUR 219 million on a preliminary basis
Made in Switzerland: blockchain enabled healthcare
Interoperable blockchain-enabled solutions could eliminate waste, enhance security and privacy, build trust and, ultimately, benefit patients and the entire pharmaceutical value chain, say the founders of PharmaLedger. Dr Kevin Robinson dialled in to find out more
Brenntag signs multi-year partnership with Workday Human Capital
The chosen Workday HCM solution will be tailored and implemented in the course of 2023 to meet the needs of Brenntag
From food to pharma: antioxidant scavengers as a viable strategy to mitigate nitrosamines in drugs
Stakeholders throughout the pharmaceutical value chain have had to deal with the recall of nitrosamine-containing medications, loss of revenue and, in some cases, reputational damage. Meanwhile, regulatory authorities have put stringent measures in motion to protect patients from potentially harmful medications, putting reformulation at the forefront of drug manufacturers’ minds, reports Anne-Cecile Bayne, Global Science and Innovation Lead, Pharma and Medical Nutrition at DSM
FUJIFILM launches viral vector feed designed to increase yields
FUJIFILM Irvine Scientific has launched its BalanCD HEK293 Viral Feed designed to boost adeno-associated viral vector (AAV) production for gene therapy applications and viral vector-based vaccines
Catalent signs development deal with Ethicann for new fast-dissolve cannabinoid treatment
Catalent and Canadian/US cannabinoid drug therapy company Ethicann Pharmaceuticals have executed a development and license agreement that will use Catalent’s proprietary Zydis orally disintegrating tablet (ODT) technology
Host cell protein analysis: strategies to improve sensitivity and reproducibility
Given that the US FDA approved 25 new cellular and gene therapy products in 2022, gene-based vaccines and therapeutics have now entered the mainstream pharmaceutical industry. However, the rising interest in gene-based strategies puts pressure on manufacturers to demonstrate optimum efficacy and safety
Manufacturing Chemist LIVE 2023: Expert Speakers Wanted
Previous years have included presentations from the likes of NASA, AstraZeneca, GSK, CMAC and we are now looking for 2023's experts
Cell and gene therapies: on the brink of commercialisation
With their one-and-done potential and pinpoint targeting capability, cell and gene therapies (CGTs) offer huge promise in the fight against a range of previously untreatable diseases. Yet, investment in this sector is not taken lightly. Typically, developers must invest billions of dollars in therapies that might take 10 years to reach the market as they battle the odds against high failure rates
Inspiration from unexpected places
How pharmaceutical companies can learn from advances in nicotine delivery
Overcoming hurdles in the biopharmaceutical pipeline with advanced analytics
In conversation with Nick Pittman and Magnus Wetterhall, both Global Marketing Managers, Bioprocessing, at Waters Corporation, Dr Kevin Robinson explored some of the big issues associated with manufacturing biologics, how they can be overcome and what Waters is doing to help scientists expedite the process of developing new therapies for patients in need
Treating infection with precise medicine may prevent our next pandemic
Antimicrobial resistance (AMR) is a grave concern that the scientific and medical community have been warning the public about for decades. There have been no new antibiotics for 35 years and no truly effective incentive for drug makers to develop them, making this threat even more urgent. As the COVID-19 pandemic demonstrated, preparedness could save countless lives and the world’s economy
Optimising coating process parameters and formulation concepts for functional taste-masking during continuous manufacturing
This article describes work done to optimise the coating process parameters (spray rate, inlet air temperature, inlet airflow), formulation and functionality of a taste-masking coat for oral solid dosage forms during continuous production
Dissolution testing: an established technique driving advances in drug delivery
This article introduces dissolution testing and highlights its ability to support modern formulation challenges. Pharmacopoeial methods are discussed with reference to specific apparatuses and method parameters. Dissolution testing equipment from Copley Scientific is showcased to illustrate the performance and productivity that are accessible with well-designed, cost-effective solutions
COVID-19: focusing attention on the next transformation in healthcare
The lightning-fast global spread of the Omicron variant of COVID-19 was a painful reminder that the only way to protect against the disease is vaccination on a global level. At the same time, South African researchers’ quick identification and analysis of Omicron demonstrated the strength and interconnectedness of the international science community, with critical data rapidly passed to those who were best able to mount a response
Manufacturing Chemist LIVE 2022 in review (part I)
Taking a front row seat during the two-day pharmaceutical conference in Birmingham, UK, Dr Kevin Robinson reports on what’s new, emerging and exciting in the world of drug delivery and beyond
Native mass spectrometry as a drug discovery engine
Using mass spectrometry to characterise and screen large intact protein targets, captured directly in their native state, is making waves as a differentiated approach to hit finding in drug discovery, explains Dr Jonathan T.S. Hopper, founder and VP of Platforms at OMass Therapeutics
Transforming tomorrow
Shaping the future with better processes, GEA has responded to the impact that digitalisation is having on the pharmaceutical manufacturing industry and pioneered a suite of virtual technologies that improve the customer experience
Previous
1
(current)
2
3
4
5
6
7
8
9
Next
Trending Articles
How to avoid sticking and picking in the tableting industry
John Norman and Kevin Queensen of Natoli Engineering explain
Adding more to the cell and gene therapy playbook
With notable advances in various forms of administration, including making the use of viral vectors safer, non-viral delivery with lipid nanoparticles and the growing application of electroporation, Dr Kevin Robinson (KSR) recently caught up with Jason Potter (JP), Director of Cell Biology R&D at Thermo Fisher Scientific, to learn more about how the company is helping the pharmaceutical industry to develop cell and gene therapies
Reading and understanding vendor-supplied tablet drawings
Understanding the tablet drawings supplied by tooling vendors is a meaningful way to learn more about your product, reports John Norman, Technical Service Representative, Natoli Engineering Company
How to proactively address EU HTAR implementation challenges before 2025
Data landscape challenges within the European Union (EU) have historically been driven by the different laws, processes and regulatory standards of its 27 member states (MS). As a result, drug therapeutics and health technology developers have faced the challenge of duplication of assessment efforts
Highly potent formulation development in oncology
Formulation development is a dynamic and experimental process. However, certain challenges are presented to CDMOs that add a layer of unnecessary pressure to the development process — some of which are avoidable. Louise Carpenter from PCI Pharma Services discusses
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all